Physician profile
Paul B Griggs
NPI 1578584264
$62,208.80
in general payments reported to CMS, 2019-2025
29 companies · $1,923 in 2025
The $1,923 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $134 · 2021: $22K · 2022: $7,921 · 2023: $1,320 · 2024: $3,347 · 2025: $1,923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,356 · Food and Beverage: $3,203 · Education: $31.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,356.00 |
| Food and Beverage | $3,202.82 |
| Education | $31.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spark Therapeutics, INC. | $46,312.85 | 2019-2022 | |
| Astellas Pharma US INC | $2,591.17 | 2023-2025 | Izervay |
| Vertex Pharmaceuticals Incorporated | $2,100.00 | 2021-2023 | |
| Allergan, INC. | $1,443.22 | 2019-2021 | |
| Becton, Dickinson and Company | $983.33 | 2022 | |
| Harrow Eye, LLC | $965.57 | 2025 | Iheezo, Triesence |
| Abbvie INC. | $932.12 | 2019-2025 | |
| Carl Zeiss Meditec, INC. | $865.52 | 2019-2022 | |
| Dutch Ophthalmic, USA | $800.66 | 2019-2022 | |
| Alcon Vision LLC | $725.00 | 2022-2025 | Rhopressa, Rocklatan |
| Alnylam Pharmaceuticals INC. | $683.33 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $476.69 | 2019-2024 | Eylea Hd, Eylea |
| Bausch & Lomb Americas INC. | $422.37 | 2022-2024 | Xipere, Xiidra, Miebo |
| Apellis Pharmaceuticals, INC. | $354.88 | 2022-2024 | Syfovre |
| Alimera Sciences, INC. | $346.39 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $324.91 | 2023-2025 | Vabysmo |
| Tarsus Pharmaceuticals, INC. | $274.12 | 2024-2025 | Xdemvy |
| Eyepoint US, INC. | $255.13 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $240.98 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $161.66 | 2019-2021 | |
| Cardinal Health 110 LLC | $150.00 | 2024 | |
| Topcon Healthcare, INC. | $146.65 | 2025 | |
| Aerie Pharmaceuticals, INC. | $137.37 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $134.44 | 2019-2025 | |
| Coherus Oncology, INC. | $125.00 | 2023 | |
| Mallinckrodt Enterprises LLC | $124.96 | 2019 | |
| Genentech, INC. | $86.35 | 2022 | |
| Lkc Technologies, INC. | $30.61 | 2022 | |
| Iridex Corporation | $13.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Griggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.